Covid – 19 Scientific Consultation Board Members

Prof. Dr. Aslı Çurgunlu

Yeditepe University Hospitals - Internal Diseases and Geriatrics Specialist

Prof. Dr. Ferdi Menda

Yeditepe University Koşuyolu Hospital Deputy

Chief Physician and Anaesthesiology and Reanimation Specialist

Prof. Dr. Özge Köner

Yeditepe University Hospitals - Anaesthesiology and Reanimation Specialist

Prof. Dr. Yaşar Küçükardalı

Yeditepe University Hospitals - Internal Diseases Specialist

Dr. Özay Ünal

Yeditepe University Koşuyolu Hospital General - Director

Nurse Nuray Koç Taşçı

Yeditepe University Koşuyolu Hospital - Deputy Director for Nursing Services

Prof. Dr. Aynur Eren Topkaya

Yeditepe University Hospitals - Medical Microbiology Specialist

Prof. Dr. Filiz Bakar

Yeditepe University Hospitals - Paediatrics Specialist

Prof. Dr. Pınar Çıragil

Yeditepe University Hospitals - Medical Microbiology Specialist

Assoc. Prof. Dr. Halit Yerebakan

Yeditepe University Kozyatağı Hospital - Chief Physician and Cardiovascular Surgery Specialist

Dr. Seha Akduman

Yeditepe University Hospitals - Pulmonology Specialist

Nurse Çınar Işık

Yeditepe University Kozyatağı Hospital - Supervisor Nurse

Prof. Dr. Fahrettin Keleştemur

Yeditepe University Hospitals Medical Coordinator and Endocrinology Specialist

Prof. Dr. Hatice Türe

Yeditepe University Hospitals Anaesthesiology and - Reanimation Specialist

Prof. Dr. Sezgin Sarıkaya

Yeditepe University Hospitals Emergency Medical - Specialist

Assoc. Prof. Dr. Tuğhan Utku

Yeditepe University Hospitals Anaesthesiology and - Reanimation Specialist

Ali Ümit Keskin

Yeditepe University Department of Engineering - Head of the Biomedical Engineering Department

Nurse Sibel Afacan Karaman

Yeditepe University Dental Hospital - Director of Nursing Services

Prof. Dr. Faruk Yencilek

Yeditepe University Koşuyolu Hospital Head - Physician and Urology Specialist

Prof. Dr. Meral Sönmezoğlu

Yeditepe University Hospitals Infectious Diseases and Clinical Microbiology Specialist

Prof. Dr. Sibel Temur

Yeditepe University Hospitals Anaesthesiology and Reanimation Specialist

Assoc. Prof. Dr. Turhan Özler

Yeditepe University Kozyatağı Hospital Deputy Chief Physician and Orthopedics and Traumatology Specialist

Nurse Hülya Demir

Yeditepe University Kozyatağı Hospital Deputy Director for Nursing Services

Seçil Temiz Aydın

Yeditepe University Hospitals Deputy Director for Quality Development

General Information

Novel Coronavirus Infection (Covıd-19) Basic Guide

Coronaviruses (CoV) are a large group of viruses of which effects ranging from mild infection charts such as a common cold that is seen everywhere throughout the society and limiting itself, to more severe infection charts such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).

Coronaviruses have various sub-types which can pass from human to human easily (HCoV-229E, HCoV-OC43, HCoV-NL63 ve HKU1-CoV). These sub-types among humans mostly cause cold symptoms. On the other hand, there are many sub-types of Coronaviruses that are observed in animals and known to cause severe infection charts by transmitting from animals to human. With detailed research, SARSCov has been transmitted from palm civets and MERS-Cov is transmitted from one-humped camels.

On 31 December 2019, World Health Organization (WHO) China Country Office have reported on pneumonia cases of which etiology is unknown in China’s Wuhan city in the state of Hubei. On 7 Januart 2020, a new type of coronavirus (2019-nCoV) has been identified that has never been observed in humans. Afterwards, the name of 2019-nCoV disease is accepted as COVID-19 and, due to the similarity of the virus to SARS CoV, it has been named Sars-CoV-2. World Health Organization classified the COVID-19 outbreak as an “international public health emergency” on 30 January and due to the observation of virus outside of China, where it was first observed, in 113 countries, the spread of the virus and the severity of it, the status is redefined as a global outbreak (pandemic) on 11 March.

The first case of our country has been recorded on 11 March after Europe and neighboring countries such as Iran.

1.1. Epidemiology

On 31 December 2019 pneumonia cases of which etiology is unknown in China’s Wuhan city in the state of Hubei, have been reported. It has also been recorded that there is a clustering at the Wuhan South China Marine Products City Market (a livestock and fish market where many various animal types are sold) at the south of Wuhan on 31 December 2019. The cases have recorded high body temperature, shortness of breath and findings that are in line with radiological bilateral lung pneumonic infiltration.  According to the COVID-19 report of the WHO about China, most of the deaths have been recorded among elderly or those who have a systemic disease (primarily high blood pressure, diabetes, cardiovascular diseases, cancer, chronical lung diseases and other immunosuppressive conditions).

. The cause of the pneumonia clustering reported on 31 December 2019 have been defined as a new type of coronavirus that has never been seen in humans before 7 January 2020. After this date, the patient numbers rose rapidly and some healthcare personnel have been reported to show symptoms. The disease spread rapidly due to its nature of human-to-human transmissions.

The first COVID-19 case have been observed in our country on 11 March 2020. Afterwards, like everywhere else in the world, our country has seen a rise of cases as well.

2. COVID-19 Infection chain consists of a source, transmission channel and susceptible people.

2.1. The source reservoir of SARS-CoV-2 is still being researched. All the present evidence about COVID-19 leads the humanity to believe that SARS-CoV-2 has a zoonotic source. Also, while uncertain at the moment, the data at hand points to the wild animals sold at Huanan Marine Products Wholesale Market. Due to its human-to-human transmission ability, COVID-19’s source is symptomatic / asymptomatic positive cases.

2.2. Transmission channel The disease is primarily spread with droplets. Also, the droplets coming out of ill people by coughing or sneezing might be carried to mouth, nose or eye mucosa by healthy people and contact with them. As asymptomatic patients showed virus presence in their respiratory tract secretion, these people can be infectious. Generally, the incubation period is 2-14 days. The infectivity period of COVID-19 is not known for certain. It is estimated that it starts prior to the symptoms for 1-2 days and ends with the disappearance of symptoms.

2.2.1. Infectivity, Viral Load starts 1-2 days before the viral spread symptoms start and at the time of throat swabs, the viral load peaks during the first emergence of symptoms. While they rapidly drop in the first seven days, this process can be extended to beyond the second week. While the virus can be observed as a positive in the stool after the second week of the disease, as there is only one case of reproduction of the virus from stool and no reported cases of infection in that way, it has been considered that it is not possible to have any sort of infection possibility apart from oral. Virus can be observed in blood and urine scarcely and it has been deemed that the virus do not present a danger to the blood banks. Also, there have been no recorded cases of virus observation in milk, vaginal swabs and sperm. Viral load is heavier on elderly people and it is an important indicator of the severity and progression of the disease. It has been observed that there is a 60-times more viral load in more severe cases than in milder cases.

Coronaviruses are generally not very durable in external environment. The time of durability depends on the humidity and temperature of the environment, the amount of organic matter that the virus has been extracted from the body and the texture of the infected surface. Generally, it has been accepted that it loses all its activity after a few hours on inanimate surfaces. While considering the activity period on inanimate surfaecs, it should not be forgotten that infection does not only depend on the virus activity, but also the duration of contact.

2.2.2. Susceptible Person/Host The whole community is susceptible to COVID-19. Healthcare personnel is the riskiest group of people in terms of encountering the disease. Men, people above 50 years of age, people with an underlying disease (High Blood Pressure, Coronary Diseases, Diabetes, Cancer, COPD, Kidney Diseases etc.), seasonal agricultural workers and rehabilitation centers as well as people in schools, army bases, prisons and immigration camps are susceptible to COVID-19. Basic Reproduction Number: R0: It is the definition of how many people an infected person can infect in a wholly susceptible society in a certain term. If the R0 factor is higher than 1, each infection causes more than one infection. The disease will transmit among humans and might cause a pandemic.

Social Immunity Level: It means the case that if a certain amount of people become immune to an infectious disease, the society becomes immune as a whole. If R0 is considered as 2.2, the social immunity level has been determined as 60% for COVID-19.

2.3. Clinical Features The efforts conducted during the pandemic provides new information about the natural course of COVID-19. Common symptoms of the infection are cough, shortness of breath, headache, running nose, muscle and joint spasms, extreme weakness, newly discovered loss of smell and taste and diarrhea. While the disease might proceed with no symptoms or mild symptoms, in more severe cases, pneumonia, severe acute respiratory tract infection, kidney failure and even death.

The death rate is reported as 11% in SARS pandemic and 35-50% in MERS-CoV pandemic. In the COVID-19 report of WHO on People’s Republic of China, the death rate has been reported as 3,8%. The death rate in our country is 2,6% as of 2 May 2020.

Asymptomatic Infection: Within the literature, there have been cases of quantitative RT-PCR (nasofaringeal swab samples) have been reported as positives in people who show no symptoms. Most of the asymptomatic cases manifest symptoms in the following stages of the infections but there are phenomenons that were asymptomatic throughout the clinical follow-up period.

2.4. Laboratory Tests Respiratory tract samples that are possibly positive case of a COVID-19 case are evaluated regarding SARS-CoV-2in Microbiology Reference Laboratories of the General Directorate of Public Health and laboratories that are designated districts.

2.4.1. Nucleic Acid Amplification Tests (NAAT) Routine verification of COVID-19 phenomenon is conducted with a NAAT test such as real-time reverse transcription polymerase chain reaction (rRT-PCR) and by determining the unique sequence of virus RNA and verification with nucleic acid sequence analysis when it is deemed necessary.

The possibility of COVID-19 cannot be excluded with one or more negative results. The factors below might cause negative results in an infected person:

- Inferior sample where patient material is too little

- Taking the sample at a too early or too late stage of the infection,

- Not processing and shipping the sample in an appropriate manner,

- Technical issues that are natural to test such as PCR inhibition or virus mutation

- Undulant dispersion of SARS-CoV-2 virus with symptomatic and asymptomatic cases.

 In case of a negative result of a patient who carries a high COVID-19 positive possibility, specifically when samples are collected from only the upper part of the respiratory tract, additional samples should be collected from the lower respiratory tract if possible and they should also be processed.

2.4.2. Sequencing

2.4.3. Serological Tests Those who are contracted with COVID-19 either symptomatically or asymptomatically develop antibody response (IgM, IgA and IgG) after a certain time. So, serological tests cannot be used as a method of diagnosis. While first antibody response (IgM) generally starts in 6-7 days, most patients generally develop an antibody response in 10 days after the first positive antibodies occur. Whether the antibodies provide an immunity and how long they can be determined (IgG) is not certain today. To determine the Serological response, ELISA or IgM/IgG determining quick antinody tests are already in use.


- If there are at least one of the symptoms of fever, cough, sore throat, headache, muscle pain, loss of smell and taste or diarrhea, the person is considered as a potential case. If the test comes back positive, the definitive diagnosis can be made.

Risk Groups

Who are Faced with a More Severe Risk?

The information on COVID-19 so far shows that some people have the risk of developing more severe symptoms and contracting the disease in genera.

  • 80% of the cases show only mild symptoms.
  • 20% of the cases are treated in hospital.
  • Generally, the disease affects people over 60 years of age much more severely.

People That Are Affected The Most:

  • People over 60 years of age
  • People with serious chronical medical diseases:
    • Heart diseases
    • High Blood Pressure
    • Diabetes
    • Chronical Respiratory Tract Diseases
    • Cancer
  • Healthcare Personnel

Rules Against The Risk Of Novel Coronavirus

1- Wash your hands frequently with soap and water for at least 20 seconds.

2- Keep a physical distance of 3-4 steps between yourself and people showing cold symptoms.

3- Keep the places you are in well-aired.

4- Wash your clothes with a regular detergent at 60-90 Degrees Celsius.

5- If you have a fever that do not go down or symptoms like coughing or shortness of breath, use a mask and apply to a healthcare institution.

6- Do not touch your eyes, mouth or nose.

7- Stay at home for 14 days when you return from another country.

8- Cover your mouth and nose with a tissue when you sneeze and cough. If a tissue is not accessible, use the inner part of your elbow.

9- Cancel or postpone your international travel plans.

10- Clean door handles, armatures, sinks and such frequently used surfaces with water and cleaning agents.

11- Avoid close contact like shaking hands or hugging.

12- If you have cold symptoms, do not have contact with the elderly and people with chronical diseases. Do not leaVe your home without a mask.

13- Do not share your personal belongings, eg. Towels.

14- Stay well hydrated, follow a balanced diet and avoid disrupting your sleep schedule.

World Statistics

There have been 27.973.127 Covid-19 cases and 905.426 deaths throughout the world up until 11.09.2020. The highest number of cases has been observed in the continent of America with 13 million cases.

Turkey’s Statıstıcs

There have been 284.943 cases and 6837 deaths in our country until 11.09.2020.

According to the data and statistics of the Ministry of Health in our country, new cases have been seen mostly in the age range of 25-49 (47.8%) and followed by the age range of 15-24 with 14%. On the other hand, the most deaths are seen among people over 80 years old (27%) and the death rate of the age range of 25-49, the range in which most cases have been observed, have a death rate of 0.34%.


  1. COVID-19 (SARS-CoV-2 ENFEKSİYONU) GENEL BİLGİLER, EPİDEMİOLOJİ VE TANI. Bilimsel Danışma Kurulu Çalışması. T.C. Sağlık Bakanlığı 29 Haziran 2020, Ankara
  2. Türkiye Covid-19 durum raporu.
  3. Dünya Sağlık Örgütü Covid 19 sitesi.
  4. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.